This website is intended for healthcare professionals only.

Newsletter          
Hospital Healthcare Europe
HOPE LOGO
Hospital Healthcare Europe

Press Releases

Take a look at a selection of our recent media coverage:

ENO Breathe programme for long COVID improves mental wellbeing and some aspects of breathlessness

19th May 2022

Use of the ENO Breathe programme led to improvements in mental health wellbeing and elements of breathlessness in patients with long COVID

The ENO Breathe programme used by patients experiencing long COVID symptoms has been found to improve mental health scores and elements of breathlessness compared to usual care. This was the conclusion from the first randomised trial to evaluate interventions for patients with long COVID by a UK team of researchers from London.

A recognised consequence for some patients after an acute infection with COVID-19 is long COVID and which has been defined as new or ongoing symptoms 4 weeks or more after the start of acute COVID-19. A wide range of symptoms experienced by those with long COVID have been documented with the most frequently reported including breathing problems, fatigue, muscle weakness or joint stiffness, sleep disturbances, problems with mental abilities, and mood changes such as anxiety or depression. Furthermore, a review of studies has suggested in both acute and long COVID, the impact of infection on health-related quality of life is substantial. In a systematic review, researchers identified how music interventions were associated with clinically meaningful improvements in health-related quality of life.

The English National Opera has created the ENO Breathe programme, to help patients recovering from the effects of COVID-19 an,d for the present study, the UK researchers set out to determine whether the programme could improve both mental and physical aspects of health-related quality of life, as well as breathlessness, in patients with long COVID. They conducted a parallel-group, single-blinded, randomised trial to compare the ENO programme with usual care. Eligible patients were adults (> 18 years of age) and who were recovering from COVID-19 with ongoing breathlessness with or without anxiety for at least 4 weeks after their acute onset of symptoms. Individuals were randomised 1:1 to the ENO Breathe programme or usual care. The programme was individualised and designed to support people with breathlessness and/or anxiety by focusing on breathing, retraining through singing techniques and delivered online. It consisted of an introductory session followed by 6, once weekly sessions.

The primary outcome of interest was a change in health-related quality of life (HRQoL) from baseline to the end of the 6-week programme and which was assessed using the RAND 36-item short form survey instrument and in particular two summary measures, the mental health (MHC) and physical health components (PHC). A number of secondary outcomes were used including a visual analogue scale (VAS) for breathlessness on rest, walking, climbing stairs and running.

ENO Breathe programme and HRQoL

A total of 150 participants with a mean age of 49 (81% female) were randomised to either the ENO programme or usual care. Across the two groups, there was a mean of 320 days since the onset of their initial COVID-19 symptoms.

Compared to usual care, those allocated to the ENO Breathe programme had a greater improvement in the MHC (regression coefficient = 2.42, 95% CI 0.03 – 4.80, p = 0.047). However, there was no significant difference between groups for the PHC component (p = 0.54).

With respect to breathlessness, the only self-reported measure to significantly reduce was based on running (p = 0.0026).

The authors concluded that the ENO Breathe intervention could improve mental health wellbeing and one aspect of breathlessness and suggested that the programme might have a role in supporting patients with persisting long COVID symptoms.

Citation
Philip KEJ et al. An online breathing and wellbeing programme (ENO Breathe) for people with persistent symptoms following COVID-19: a parallel-group, single-blind, randomised controlled trial Lancet Respir Med 2022